（来源：研报虎）总结：行业持续分行业总结：2024年及2025H1医药业绩承压、分化显著，消费类疲弱，创新药+原料药+CXO表现较好行业整体：2024年，453家医药公司实现营收2.46万亿元，同比下滑0.55%；共实现归母净利润1486.5亿元，同比下降8.8%；2025H1，实现营收1.22万亿元，同比下降2.5%；实现归母净利润1020亿元，同比下降2.1%。创新药：2025H1创新药公司共...
Source Link（来源：研报虎）总结：行业持续分行业总结：2024年及2025H1医药业绩承压、分化显著，消费类疲弱，创新药+原料药+CXO表现较好行业整体：2024年，453家医药公司实现营收2.46万亿元，同比下滑0.55%；共实现归母净利润1486.5亿元，同比下降8.8%；2025H1，实现营收1.22万亿元，同比下降2.5%；实现归母净利润1020亿元，同比下降2.1%。创新药：2025H1创新药公司共...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.